All Stories

  1. Impact of obstructive sleep apnoea on cognitive function in multiple sclerosis: A longitudinal study

    Article • Journal of Sleep Research, August 2020, Wiley

    Professor Michael Hutchinson

  2. The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis

    Article • Multiple Sclerosis and Related Disorders, April 2020, Elsevier

    Professor Michael Hutchinson

  3. Slowed Luminance Reaction Times in Cervical Dystonia: Disordered Superior Colliculus Processing

    Article • Movement Disorders, January 2020, Wiley

    Professor Michael Hutchinson

  4. Temporal discrimination threshold and blink reflex recovery cycle in cervical dystonia – two sides of the same coin?

    Article • Parkinsonism & Related Disorders, November 2019, Elsevier

    Professor Michael Hutchinson

  5. A Study of the Midbrain Network for Covert Attentional Orienting in Cervical Dystonia Patients using Dynamic Causal Modelling

    Article • July 2019, Institute of Electrical & Electronics Engineers (IEEE)

    Professor Michael Hutchinson

  6. Characterizing Brain Network Topology in Cervical Dystonia Patients and Unaffected Relatives via Graph Theory

    Article • July 2019, Institute of Electrical & Electronics Engineers (IEEE)

    Professor Michael Hutchinson

  7. Neural Correlates of Abnormal Temporal Discrimination in Unaffected Relatives of Cervical Dystonia Patients

    Article • Frontiers in Integrative Neuroscience, March 2019, Frontiers

    Professor Michael Hutchinson

  8. Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia

    Article • Journal of Visualized Experiments, January 2018, MyJove Corporation

    Professor Michael Hutchinson

  9. The premotor syndrome of cervical dystonia: Disordered processing of salient environmental stimuli

    Article • Movement Disorders, December 2017, Wiley

    Professor Michael Hutchinson

  10. PO089 Disrupted superior collicular activity may reveal cervical dystonia disease pathomechanisms

    Article • Journal of Neurology Neurosurgery & Psychiatry, December 2017, BMJ

    Professor Michael Hutchinson

  11. Disrupted superior collicular activity may reveal cervical dystonia disease pathomechanisms

    Article • Scientific Reports, December 2017, Springer Science + Business Media

    Professor Michael Hutchinson

  12. Temporal Discrimination: Mechanisms and Relevance to Adult-Onset Dystonia

    Article • Frontiers in Neurology, November 2017, Frontiers

    Professor Michael Hutchinson

  13. Practice does not make perfect: Temporal discrimination in musicians with and without dystonia

    Article • Movement Disorders, October 2017, Wiley

    Professor Michael Hutchinson, Richard Reilly

  14. Marta Elian: Obituary

    Article • Multiple Sclerosis Journal, March 2017, SAGE Publications

    Professor Michael Hutchinson

  15. Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland

    Article • European Journal of Neurology, September 2016, Wiley

    Professor Michael Hutchinson

  16. Integrated multidisciplinary clinics should be the gold standard in managing progressive MS – Commentary

    Article • Multiple Sclerosis Journal, July 2016, SAGE Publications

    Professor Michael Hutchinson

  17. All relapsing multiple sclerosis patients should be managed at a specialist clinic – Commentary

    Article • Multiple Sclerosis Journal, April 2016, SAGE Publications

    Professor Michael Hutchinson

  18. A useful annual review of cognition in relapsing MS is beyond most neurologists – Commentary

    Article • Multiple Sclerosis Journal, April 2016, SAGE Publications

    Professor Michael Hutchinson

  19. Modeling the course and outcomes of MS is statistical twaddle—Commentary

    Article • Multiple Sclerosis Journal, February 2016, SAGE Publications

    Professor Michael Hutchinson

  20. Neurodegeneration in multiple sclerosis is a process separate from inflammation: No

    Article • Multiple Sclerosis Journal, October 2015, SAGE Publications

    Professor Michael Hutchinson

  21. THE MS-SMART TRIAL IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: A MULTI-ARM, MULTI-CENTRE TRIAL OF NEUROPROTECTION

    Article • Journal of Neurology Neurosurgery & Psychiatry, October 2015, BMJ

    Professor Michael Hutchinson

  22. Multiple sclerosis relapse phenotype is an important, neglected determinant of disease-outcome: Commentary

    Article • Multiple Sclerosis Journal, October 2015, SAGE Publications

    Professor Michael Hutchinson

  23. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary

    Article • Multiple Sclerosis Journal, August 2015, SAGE Publications

    Professor Michael Hutchinson

  24. Young Women do it Better: Sexual Dimorphism in Temporal Discrimination

    Article • Frontiers in Neurology, July 2015, Frontiers

    Professor Michael Hutchinson

  25. Non-parametric bootstrapping method for measuring the temporal discrimination threshold for movement disorders

    Article • Journal of Neural Engineering, June 2015, Institute of Physics Publishing

    Professor Michael Hutchinson

  26. Symptomatic therapy in multiple sclerosis: Big pharma should do more – commentary

    Article • Multiple Sclerosis Journal, June 2015, SAGE Publications

    Professor Michael Hutchinson

  27. A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis

    Article • PLOS One, June 2015, PLOS

    Professor Michael Hutchinson

  28. The best clinical paper on multiple sclerosis in 2014: Herodotus and Chataway − Commentary

    Article • Multiple Sclerosis Journal, May 2015, SAGE Publications

    Professor Michael Hutchinson

  29. Sun exposure is an environmental factor for the development of blepharospasm

    Article • Journal of Neurology Neurosurgery & Psychiatry, April 2015, BMJ

    Professor Michael Hutchinson

  30. Unmet needs of multiple sclerosis patients in the community

    Article • Multiple Sclerosis and Related Disorders, March 2015, Elsevier

    Professor Michael Hutchinson

  31. The best basic science paper in multiple sclerosis in 2014: Citicoline, remyelination and neuroprotection: Commentary

    Article • Multiple Sclerosis Journal, February 2015, SAGE Publications

    Professor Michael Hutchinson

  32. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

    Article • Neurology, February 2015, Wolters Kluwer Health

    Professor Michael Hutchinson

  33. Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis - Commentary

    Article • Multiple Sclerosis Journal, January 2015, SAGE Publications

    Professor Michael Hutchinson

  34. We can compare the relative efficacy multiple sclerosis medications by examining the results of independent clinical trials: Commentary

    Article • Multiple Sclerosis Journal, December 2014, SAGE Publications

    Professor Michael Hutchinson

  35. Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

    Article • European Journal of Neurology, December 2014, Wiley

    Professor Michael Hutchinson

  36. Efficacy of delayed‐release dimethyl fumarate in relapsing‐remitting multiple sclerosis: integrated analysis of the phase 3 trials

    Article • Annals of Clinical and Translational Neurology, December 2014, Wiley

    Professor Michael Hutchinson

  37. The best basic science paper in multiple sclerosis in 2013: Disease specific molecular events in cortical multiple sclerosis lesions

    Article • Multiple Sclerosis Journal, November 2014, SAGE Publications

    Professor Michael Hutchinson

  38. Economic costs associated with an MS relapse

    Article • Multiple Sclerosis and Related Disorders, November 2014, Elsevier

    Professor Michael Hutchinson

  39. Spinal cord MRI should always be performed in clinically isolated syndrome patients: Commentary

    Article • Multiple Sclerosis Journal, October 2014, SAGE Publications

    Professor Michael Hutchinson

  40. Multiparity in women with multiple sclerosis causes less long-term disability: Commentary

    Article • Multiple Sclerosis Journal, October 2014, SAGE Publications

    Professor Michael Hutchinson

  41. Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Commentary

    Article • Multiple Sclerosis Journal, August 2014, SAGE Publications

    Professor Michael Hutchinson

  42. Epidemiology of Wilson's disease in Ireland

    Article • Movement Disorders, August 2014, Wiley

    Professor Michael Hutchinson

  43. Electrophysiological and behavioral measures of visuo-motor learning for application in movement disorders

    Article • August 2014, Institute of Electrical & Electronics Engineers (IEEE)

    Professor Michael Hutchinson

  44. Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: Commentary

    Article • Multiple Sclerosis Journal, July 2014, SAGE Publications

    Professor Michael Hutchinson

  45. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel

    Article • Multiple Sclerosis and Related Disorders, July 2014, Elsevier

    Professor Michael Hutchinson

  46. An evaluation of the role of environmental factors in the disease penetrance of cervical dystonia

    Article • Journal of Neurology Neurosurgery & Psychiatry, June 2014, BMJ

    Professor Michael Hutchinson

  47. The best clinical paper of 2013: Commentary

    Article • Multiple Sclerosis Journal, June 2014, SAGE Publications

    Professor Michael Hutchinson

  48. Cervical Dystonia: A Disorder of the Midbrain Network for Covert Attentional Orienting

    Article • Frontiers in Neurology, April 2014, Frontiers

    Professor Michael Hutchinson

  49. Dexterity Training Improves Manual Precision in Patients Affected by Essential Tremor

    Article • Archives of Physical Medicine and Rehabilitation, April 2014, Elsevier

    Professor Michael Hutchinson

  50. MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: Commentary

    Article • Multiple Sclerosis Journal, March 2014, SAGE Publications

    Professor Michael Hutchinson

  51. Temporal discrimination, a cervical dystonia endophenotype: Penetrance and functional correlates

    Article • Movement Disorders, January 2014, Wiley

    Professor Michael Hutchinson

  52. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison

    Article • Current Medical Research and Opinion, November 2013, Informa Healthcare

    Professor Michael Hutchinson

  53. Evoked potentials are of little use in the diagnosis or monitoring of MS: Commentary

    Article • Multiple Sclerosis Journal, November 2013, SAGE Publications

    Professor Michael Hutchinson

  54. Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: Commentary

    Article • Multiple Sclerosis Journal, November 2013, SAGE Publications

    Professor Michael Hutchinson

  55. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study

    Article • Multiple Sclerosis Journal, October 2013, SAGE Publications

    Professor Michael Hutchinson

  56. The endophenotype and the phenotype: Temporal discrimination and adult-onset dystonia

    Article • Movement Disorders, October 2013, Wiley

    Professor Michael Hutchinson

  57. DOES JCV ANTIBODY POSITIVITY ENCOURAGE CESSATION OF NATALIZUMAB THERAPY IN MULTIPLE SCLEROSIS?

    Article • Journal of Neurology Neurosurgery & Psychiatry, October 2013, BMJ

    Professor Michael Hutchinson

  58. Longitudinal assessment of the multiple sclerosis impact scale (MSIS-29) amongst A treated relapsing remitting multiple sclerosis cohort

    Article • Journal of the Neurological Sciences, October 2013, Elsevier

    Professor Michael Hutchinson

  59. One can prevent post-partum MS relapses by exclusive breast feeding: Commentary

    Article • Multiple Sclerosis Journal, October 2013, SAGE Publications

    Professor Michael Hutchinson

  60. Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM

    Article • Expert Opinion on Pharmacotherapy, August 2013, Informa Healthcare

    Professor Michael Hutchinson

  61. The best basic science paper on multiple sclerosis in 2012: Commentary

    Article • Multiple Sclerosis Journal, July 2013, SAGE Publications

    Professor Michael Hutchinson

  62. Pallidal stimulation for cervical dystonia does not correct abnormal temporal discrimination

    Article • Movement Disorders, July 2013, Wiley

    Professor Michael Hutchinson

  63. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study

    Article • Deutsche Zeitschrift für Nervenheilkunde, June 2013, Springer Science + Business Media

    Professor Michael Hutchinson

  64. Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: Commentary

    Article • Multiple Sclerosis Journal, May 2013, SAGE Publications

    Professor Michael Hutchinson

  65. A novelCACNA1Amutation associated with adult-onset, paroxysmal head tremor

    Article • Movement Disorders, May 2013, Wiley

    Professor Michael Hutchinson

  66. CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald Criteria 2010: Commentary

    Article • Multiple Sclerosis Journal, May 2013, SAGE Publications

    Professor Michael Hutchinson

  67. The best clinical paper on multiple sclerosis in 2012: Commentary

    Article • Multiple Sclerosis Journal, April 2013, SAGE Publications

    Professor Michael Hutchinson

  68. Symptom overlap in anxiety and multiple sclerosis

    Article • Multiple Sclerosis Journal, February 2013, SAGE Publications

    Professor Michael Hutchinson

  69. If I had CIS with MRI diagnostic of MS, I would take vitamin D 10,000 IU daily: Commentary

    Article • Multiple Sclerosis Journal, February 2013, SAGE Publications

    Professor Michael Hutchinson

  70. Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double- blind placebo-controlled trial

    Article • Trials, January 2013, Springer Science + Business Media

    Professor Michael Hutchinson

  71. In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: Commentary

    Article • Multiple Sclerosis Journal, January 2013, SAGE Publications

    Professor Michael Hutchinson

  72. The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: Commentary

    Article • Multiple Sclerosis Journal, December 2012, SAGE Publications

    Professor Michael Hutchinson

  73. A proposed modification to the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis

    Article • Multiple Sclerosis Journal, November 2012, SAGE Publications

    Professor Michael Hutchinson

  74. AGE-RELATED PENETRANCE OF ABNORMAL TEMPORAL DISCRIMINATION THRESHOLDS IN UNAFFECTED FIRST-DEGREE RELATIVES OF ADULT ONSET PRIMARY TORSION DYSTONIA PATIENTS

    Article • Journal of Neurology Neurosurgery & Psychiatry, November 2012, BMJ

    Professor Michael Hutchinson

  75. THE COST OF A MULTIPLE SCLEROSIS RELAPSE

    Article • Journal of Neurology Neurosurgery & Psychiatry, November 2012, BMJ

    Professor Michael Hutchinson

  76. Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: Commentary

    Article • Multiple Sclerosis Journal, October 2012, SAGE Publications

    Professor Michael Hutchinson

  77. Rehabilitation therapy in MS: a short-term, expensive, placebo: Commentary

    Article • Multiple Sclerosis Journal, September 2012, SAGE Publications

    Professor Michael Hutchinson

  78. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2012, New England Journal of Medicine (NEJM/MMS)

    Professor Michael Hutchinson

  79. Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: Commentary

    Article • Multiple Sclerosis Journal, August 2012, SAGE Publications

    Professor Michael Hutchinson

  80. Does natalizumab therapy worsen neuromyelitis optica?

    Article • Neurology, August 2012, Wolters Kluwer Health

    Professor Michael Hutchinson

  81. Response to comment on the article by Allen et al. ‘A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers’

    Article • Multiple Sclerosis Journal, August 2012, SAGE Publications

    Professor Michael Hutchinson

  82. Deaths and disability from natalizumab are no longer tolerable: Commentary

    Article • Multiple Sclerosis Journal, July 2012, SAGE Publications

    Professor Michael Hutchinson

  83. Current Treatments for Progressive Multiple Sclerosis: Disease-Modifying Therapies

    Article • June 2012, Springer Science + Business Media

    Professor Michael Hutchinson

  84. There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion - Commentary

    Article • Multiple Sclerosis Journal, June 2012, SAGE Publications

    Professor Michael Hutchinson

  85. We are about to cure MS in the next 10 years, even though we do not know its cause: Commentary

    Article • Multiple Sclerosis Journal, May 2012, SAGE Publications

    Professor Michael Hutchinson

  86. The neurologist’s dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately – Commentary

    Article • Multiple Sclerosis Journal, April 2012, SAGE Publications

    Professor Michael Hutchinson

  87. Penetrance of Abnormal Temporal Discrimination Thresholds in Unaffected First-Degree Relatives of Adult Onset Primary Torsion Dystonia Patients (P01.218)

    Article • Neurology, April 2012, Wolters Kluwer Health

    Professor Michael Hutchinson

  88. Functional Correlates of Temporal Discrimination in Adult Onset Primary Torsion Dystonia Patients and Unaffected First-Degree Relatives (P01.220)

    Article • Neurology, April 2012, Wolters Kluwer Health

    Professor Michael Hutchinson

  89. The Importance of CSF Oligoclonal Bands in the Diagnosis of Primary Progressive Multiple Sclerosis (P01.139)

    Article • Neurology, April 2012, Wolters Kluwer Health

    Professor Michael Hutchinson

  90. Relapsing Anti-Glycine Receptor Antibody Mediated Encephalitis with Rigidity and Myoclonus (P01.235)

    Article • Neurology, April 2012, Wolters Kluwer Health

    Professor Michael Hutchinson

  91. Do not treat from CIS onset: evaluate disease course and prognosis first - Commentary

    Article • Multiple Sclerosis Journal, April 2012, SAGE Publications

    Professor Michael Hutchinson

  92. A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers

    Article • Multiple Sclerosis Journal, March 2012, SAGE Publications

    Professor Michael Hutchinson

  93. In assessing multiple sclerosis disease activity patient report measures are a waste of time: cut to the MRI scan! – Commentary

    Article • Multiple Sclerosis Journal, March 2012, SAGE Publications

    Professor Michael Hutchinson

  94. 1612 Sporadic AOPTD is a genetic disorder: evidence from the temporal discrimination threshold

    Article • Journal of Neurology Neurosurgery & Psychiatry, February 2012, BMJ

    Professor Michael Hutchinson

  95. 122 Functional correlates of abnormal temporal discrimination in adult onset primary torsion dystonia patients and first-degree relatives

    Article • Journal of Neurology Neurosurgery & Psychiatry, February 2012, BMJ

    Professor Michael Hutchinson

  96. 136 Initial experience of alemtuzumab for patients who fail natalizumab therapy

    Article • Journal of Neurology Neurosurgery & Psychiatry, February 2012, BMJ

    Professor Michael Hutchinson

  97. 040 Electronic neurology referrals: a solution for an overburdened healthcare system?

    Article • Journal of Neurology Neurosurgery & Psychiatry, February 2012, BMJ

    Professor Michael Hutchinson

  98. 0854 The sensitivity of JC virus DNA detection vs JC virus antibody testing in a natalizumab-treated group of relapsing MS patients

    Article • Journal of Neurology Neurosurgery & Psychiatry, February 2012, BMJ

    Professor Michael Hutchinson

  99. Epidemiology of multiple sclerosis has had its day: there are no more unanswered questions - Commentary

    Article • Multiple Sclerosis Journal, December 2011, SAGE Publications

    Professor Michael Hutchinson

  100. Truly benign multiple sclerosis is rare: let’s stop fooling ourselves - Commentary

    Article • Multiple Sclerosis Journal, December 2011, SAGE Publications

    Professor Michael Hutchinson

  101. Relapses do not matter in relation to long-term disability: Commentary

    Article • Multiple Sclerosis Journal, November 2011, SAGE Publications

    Professor Michael Hutchinson

  102. A budget impact analysis of natalizumab use in Ireland

    Article • Irish Journal of Medical Science (1971 -), October 2011, Springer Science + Business Media

    Professor Michael Hutchinson

  103. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS

    Article • Deutsche Zeitschrift für Nervenheilkunde, October 2011, Springer Science + Business Media

    Professor Michael Hutchinson

  104. Spontaneous intracranial hypotension: case reports and literature review

    Article • Irish Journal of Medical Science (1971 -), October 2011, Springer Science + Business Media

    Professor Michael Hutchinson

  105. The major cause of multiple sclerosis is environmental: genetics has a minor role - Commentary

    Article • Multiple Sclerosis Journal, October 2011, SAGE Publications

    Professor Michael Hutchinson

  106. Controversies in multiple sclerosis: a series of debates

    Article • Multiple Sclerosis Journal, October 2011, SAGE Publications

    Professor Michael Hutchinson

  107. Translation Initiator EIF4G1 Mutations in Familial Parkinson Disease

    Article • The American Journal of Human Genetics, September 2011, Elsevier

    Professor Carles Vilarino-Guell, Professor Michael Hutchinson

  108. Using atypical symptoms and red flags to identify non-demyelinating disease

    Article • Journal of Neurology Neurosurgery & Psychiatry, August 2011, BMJ

    Professor Michael Hutchinson

  109. Sporadic adult onset primary torsion dystonia is a genetic disorder by the temporal discrimination test

    Article • Brain, August 2011, Oxford University Press (OUP)

    Professor Michael Hutchinson

  110. Temporal discrimination thresholds in adult-onset primary torsion dystonia: an analysis by task type and by dystonia phenotype

    Article • Deutsche Zeitschrift für Nervenheilkunde, June 2011, Springer Science + Business Media

    Professor Michael Hutchinson

  111. Change in PASAT performance correlates with change in P3 ERP amplitude over a 12-month period in multiple sclerosis patients

    Article • Journal of the Neurological Sciences, June 2011, Elsevier

    Professor Michael Hutchinson

  112. Preliminary evidence for correlation between PASAT performance and P3a and P3b amplitudes in progressive multiple sclerosis

    Article • European Journal of Neurology, April 2011, Wiley

    Professor Michael Hutchinson

  113. Multiple sclerosis, from referral to confirmed diagnosis: an audit of clinical practice

    Article • Multiple Sclerosis Journal, April 2011, SAGE Publications

    Professor Michael Hutchinson

  114. Safety first, efficacy second in disease modifying therapies

    Article • Multiple Sclerosis Journal, April 2011, SAGE Publications

    Professor Michael Hutchinson

  115. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

    Article • Annals of Neurology, February 2011, Wiley

    Professor Michael Hutchinson

  116. Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype

    Article • Journal of Neurology Neurosurgery & Psychiatry, January 2011, BMJ

    Professor Michael Hutchinson

  117. ‘Switching off’ SUNCT by sudden head movement: a new symptom

    Article • Deutsche Zeitschrift für Nervenheilkunde, November 2010, Springer Science + Business Media

    Professor Michael Hutchinson

  118. POMD04 Utility of temporal discrimination threshold testing in different adult-onset primary torsion dystonia phenotypes

    Article • Journal of Neurology Neurosurgery & Psychiatry, October 2010, BMJ

    Professor Michael Hutchinson

  119. POMD05 Temporal discrimination threshold in patients with sporadic adult-onset primary torsion dystonia and their first degree relatives

    Article • Journal of Neurology Neurosurgery & Psychiatry, October 2010, BMJ

    Professor Michael Hutchinson

  120. POMD06 Utility of visual, tactile and mixed tasks in the determination of temporal discrimination thresholds in adult-onset primary torsion dystonia

    Article • Journal of Neurology Neurosurgery & Psychiatry, October 2010, BMJ

    Professor Michael Hutchinson

  121. POI09 Trends in BK and JC polyomavirus and relationship to CD4+/CD8+ ratio in patients with relapsing remitting multiple sclerosis on natalizumab therapy

    Article • Journal of Neurology Neurosurgery & Psychiatry, October 2010, BMJ

    Professor Michael Hutchinson

  122. POI10 Using atypical symptoms to predict nondemyelinating disease in patients as "query multiple sclerosis"

    Article • Journal of Neurology Neurosurgery & Psychiatry, October 2010, BMJ

    Professor Michael Hutchinson

  123. Natalizumab Therapy of Multiple Sclerosis

    Article • Journal of Interferon & Cytokine Research, October 2010, Mary Ann Liebert Inc

    Professor Michael Hutchinson

  124. A high-density ERP study reveals latency, amplitude, and topographical differences in multiple sclerosis patients versus controls☆

    Article • Clinical Neurophysiology, September 2010, Elsevier

    Professor Michael Hutchinson

  125. OAS1: A multiple sclerosis susceptibility gene that influences disease severity

    Article • Neurology, August 2010, Wolters Kluwer Health

    Professor Michael Hutchinson

  126. New perspectives in the natural history of multiple sclerosis

    Article • Neurology, June 2010, Wolters Kluwer Health

    Professor Michael Hutchinson

  127. Impaired information processing speed and attention allocation in multiple sclerosis patients versus controls: A high-density EEG study

    Article • Journal of the Neurological Sciences, June 2010, Elsevier

    Professor Michael Hutchinson

  128. Obituary

    Article • Multiple Sclerosis Journal, May 2010, SAGE Publications

    Professor Michael Hutchinson

  129. Clinically isolated syndrome: a protected zone for trials of new therapies?

    Article • Multiple Sclerosis Journal, April 2010, SAGE Publications

    Professor Michael Hutchinson

  130. Patient-centered outcomes: Translating clinical efficacy into benefits on health-related quality of life

    Article • Neurology, April 2010, Wolters Kluwer Health

    Professor Michael Hutchinson

  131. Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?

    Article • Multiple Sclerosis Journal, December 2009, SAGE Publications

    Professor Michael Hutchinson

  132. Comparing endophenotypes in adult-onset primary torsion dystonia

    Article • Movement Disorders, November 2009, Wiley

    Professor Michael Hutchinson

  133. Sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO) in a sibling pair with a homozygous p.A467T POLG mutation

    Article • Muscle & Nerve, October 2009, Wiley

    Professor Michael Hutchinson

  134. Natalizumab therapy of multiple sclerosis

    Article • Cytokine, October 2009, Elsevier

    Professor Michael Hutchinson

  135. Clinical Reasoning: An unusual case of papilledema after orthotopic liver transplantation

    Article • Neurology, August 2009, Wolters Kluwer Health

    Professor Michael Hutchinson

  136. Dementia in SPG4 hereditary spastic paraplegia: Clinical, genetic, and neuropathologic evidence

    Article • Neurology, August 2009, Wolters Kluwer Health

    Professor Michael Hutchinson

  137. Assessing disability progression with the Multiple Sclerosis Functional Composite

    Article • Multiple Sclerosis Journal, August 2009, SAGE Publications

    Professor Michael Hutchinson

  138. Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients

    Article • Pharmacogenomics, July 2009, Future Medicine

    Professor Michael Hutchinson

  139. Temporal Discrimination Threshold: VBM evidence for an endophenotype in adult onset primary torsion dystonia

    Article • Brain, June 2009, Oxford University Press (OUP)

    Professor Michael Hutchinson

  140. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia

    Article • Brain, June 2009, Oxford University Press (OUP)

    Professor Michael Hutchinson

  141. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

    Article • Deutsche Zeitschrift für Nervenheilkunde, May 2009, Springer Science + Business Media

    Professor Michael Hutchinson

  142. Predicting and preventing the future: actively managing multiple sclerosis

    Article • Practical Neurology, May 2009, BMJ

    Professor Michael Hutchinson

  143. Striatal morphology correlates with sensory abnormalities in unaffected relatives of cervical dystonia patients

    Article • Deutsche Zeitschrift für Nervenheilkunde, April 2009, Springer Science + Business Media

    Professor Michael Hutchinson

  144. Tolosa-Hunt syndrome responsive to infliximab therapy

    Article • Deutsche Zeitschrift für Nervenheilkunde, April 2009, Springer Science + Business Media

    Professor Michael Hutchinson

  145. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

    Article • Deutsche Zeitschrift für Nervenheilkunde, March 2009, Springer Science + Business Media

    Professor Michael Hutchinson

  146. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

    Article • The Lancet Neurology, March 2009, Elsevier

    Professor Michael Hutchinson

  147. Fluctuations in T helper subpopulations in relapsing-remitting multiple sclerosis

    Article • Acta Neurologica Scandinavica, January 2009, Wiley

    Professor Michael Hutchinson

  148. Clinical correlates of abnormal brain-stem auditory evoked responses in multiple sclerosis

    Article • Acta Neurologica Scandinavica, January 2009, Wiley

    Professor Michael Hutchinson

  149. CSF myelin basic protein in multiple sclerosis

    Article • Acta Neurologica Scandinavica, January 2009, Wiley

    Professor Michael Hutchinson

  150. Clinical Reasoning: A case of Wegener granulomatosis complicated by seizures and headaches: Curiouser and curiouser

    Article • Neurology, January 2009, Wolters Kluwer Health

    Professor Michael Hutchinson

  151. Reactivation of BK polyomavirus in patients with multiple sclerosis receiving natalizumab therapy

    Article • Journal of NeuroVirology, January 2009, Springer Science + Business Media

    Professor Michael Hutchinson

  152. Cervical dystonia presenting as a phenocopy in an Irish SCA2 family

    Article • Movement Disorders, December 2008, Wiley

    Professor Michael Hutchinson

  153. Counting the cost of complementary and alternative therapies in an Irish neurological clinic

    Article • European Journal of Neurology, December 2008, Wiley

    Professor Michael Hutchinson

  154. PROGRESSIVE ENCEPHALOMYELITIS, RIGIDITY, AND MYOCLONUS: A NOVEL GLYCINE RECEPTOR ANTIBODY

    Article • Neurology, October 2008, Wolters Kluwer Health

    Professor Michael Hutchinson

  155. Differential diagnosis of suspected multiple sclerosis: a consensus approach

    Article • Multiple Sclerosis Journal, September 2008, SAGE Publications

    Professor Michael Hutchinson

  156. New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin

    Article • Deutsche Zeitschrift für Nervenheilkunde, September 2008, Springer Science + Business Media

    Professor Michael Hutchinson

  157. Intravenous therapy for the treatment of multiple sclerosis

    Article • Future Prescriber, July 2008, Wiley

    Professor Michael Hutchinson

  158. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease

    Article • Journal of Neurology Neurosurgery & Psychiatry, June 2008, BMJ

    Professor Michael Hutchinson

  159. REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31

    Article • Brain, February 2008, Oxford University Press (OUP)

    Professor Michael Hutchinson

  160. Unusual MRI abnormalities in anti-Yo positive "pure" paraneoplastic cerebellar degeneration

    Article • Deutsche Zeitschrift für Nervenheilkunde, November 2007, Springer Science + Business Media

    Professor Michael Hutchinson

  161. Molding the sensory cortex: Spatial acuity improves after botulinum toxin treatment for cervical dystonia

    Article • Movement Disorders, October 2007, Wiley

    Professor Michael Hutchinson

  162. The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite

    Article • Multiple Sclerosis Journal, October 2007, SAGE Publications

    Professor Michael Hutchinson

  163. Sporadic adult onset dystonia: sensory abnormalities as an endophenotype in unaffected relatives

    Article • Journal of Neurology Neurosurgery & Psychiatry, September 2007, BMJ

    Professor Michael Hutchinson

  164. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL

    Article • Neurology, August 2007, Wolters Kluwer Health

    Professor Michael Hutchinson, Professor Fredrik Piehl

  165. Health-related quality of life in multiple sclerosis: effects of natalizumab

    Article • Annals of Neurology, August 2007, Wiley

    Professor Michael Hutchinson

  166. Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis

    Article • Deutsche Zeitschrift für Nervenheilkunde, August 2007, Springer Science + Business Media

    Professor Michael Hutchinson

  167. The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical)

    Article • Journal of Neurology Neurosurgery & Psychiatry, August 2007, BMJ

    Professor Michael Hutchinson

  168. Is a 20% change in MSFC components clinically meaningful?

    Article • Multiple Sclerosis Journal, July 2007, SAGE Publications

    Professor Michael Hutchinson

  169. What difference does a neurologist make in a general hospital? Estimating the impact of neurology consultations on in-patient care

    Article • Irish Journal of Medical Science (1971 -), June 2007, Springer Science + Business Media

    Professor Michael Hutchinson

  170. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

    Article • Neurology, April 2007, Wolters Kluwer Health

    Professor Michael Hutchinson

  171. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

    Article • Neurology, April 2007, Wolters Kluwer Health

    Professor Michael Hutchinson

  172. Natalizumab: A new treatment for relapsing remitting multiple sclerosis

    Article • Therapeutics and Clinical Risk Management, April 2007, Taylor & Francis

    Professor Michael Hutchinson

  173. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis

    Article • Multiple Sclerosis Journal, January 2007, SAGE Publications

    Professor Michael Hutchinson

  174. Linkage to a known gene but no mutation identified: comprehensive reanalysis ofSPG4 HSP pedigrees reveals large deletions as the sole cause

    Article • Human Mutation, January 2007, Wiley

    Professor Michael Hutchinson

  175. Paroxysmal torticollis and blepharospasm following bilateral cerebellar Infarction

    Article • Deutsche Zeitschrift für Nervenheilkunde, December 2006, Springer Science + Business Media

    Professor Michael Hutchinson

  176. FC46.3 Assessment of intracortical inhibition in familial adult-onset dystonia using paired transcranial magnetic stimulation

    Article • Clinical Neurophysiology, September 2006, Elsevier

    Professor Michael Hutchinson

  177. Human leucocyte antigen class II polymorphism in Irish patients with multiple sclerosis

    Article • Tissue Antigens, September 2006, Wiley

    Professor Michael Hutchinson

  178. The Face-Symbol Test and the Symbol-Digit Test are not reliable surrogates for the Paced Auditory Serial Addition Test in multiple sclerosis

    Article • Multiple Sclerosis Journal, September 2006, SAGE Publications

    Professor Michael Hutchinson

  179. Hereditary spastic paraparesis and psychosis

    Article • European Journal of Neurology, August 2006, Wiley

    Professor Michael Hutchinson

  180. Mapping candidate non-MHC susceptibility regions to multiple sclerosis

    Article • Genes & Immunity, July 2006, Springer Science + Business Media

    Professor Michael Hutchinson

  181. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2006, New England Journal of Medicine (NEJM/MMS)

    Professor Michael Hutchinson

  182. Unrecognised symptoms of depression in a community–based population with multiple sclerosis

    Article • Deutsche Zeitschrift für Nervenheilkunde, September 2005, Springer Science + Business Media

    Professor Michael Hutchinson

  183. Sensory abnormalities in unaffected relatives in familial adult-onset dystonia

    Article • Neurology, September 2005, Wolters Kluwer Health

    Professor Michael Hutchinson

  184. Population frequency of HLA haplotypes contributes to the prevalence difference of multiple sclerosis in Ireland

    Article • Deutsche Zeitschrift für Nervenheilkunde, September 2005, Springer Science + Business Media

    Professor Michael Hutchinson

  185. Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy

    Article • Neurology, July 2005, Wolters Kluwer Health

    Professor Michael Hutchinson

  186. Fatal toxic leukoencephalopathy: clinical, radiological, and necropsy findings in two patients

    Article • Journal of Neurology Neurosurgery & Psychiatry, July 2005, BMJ

    Professor Michael Hutchinson

  187. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns

    Article • Multiple Sclerosis Journal, February 2005, SAGE Publications

    Professor Michael Hutchinson

  188. Inherited myoclonus-dystonia and epilepsy: Further evidence of an association?

    Article • Movement Disorders, December 2004, Wiley

    Professor Michael Hutchinson

  189. Age at onset as a factor in determining the phenotype of primary torsion dystonia

    Article • Neurology, October 2004, Wolters Kluwer Health

    Professor Michael Hutchinson

  190. Transition from paediatric to adult neurological services * Authors' reply

    Article • Journal of Neurology Neurosurgery & Psychiatry, August 2004, BMJ

    Professor Michael Hutchinson

  191. Familial adolescent-onset scoliosis and later segmental dystonia in an Irish family

    Article • Deutsche Zeitschrift für Nervenheilkunde, July 2004, Springer Science + Business Media

    Professor Michael Hutchinson

  192. Confirming the validity and responsiveness of the Multiple Sclerosis Walking Scale-12 (MSWS-12)

    Article • Neurology, June 2004, Wolters Kluwer Health

    Professor Michael Hutchinson

  193. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse

    Article • Brain, April 2004, Oxford University Press (OUP)

    Professor Michael Hutchinson

  194. Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity

    Article • Journal of Neurology Neurosurgery & Psychiatry, April 2004, BMJ

    Professor Michael Hutchinson

  195. Further evidence of dementia in SPG4-linked autosomal dominant hereditary spastic paraplegia

    Article • Neurology, February 2004, Wolters Kluwer Health

    Professor Michael Hutchinson

  196. Cervical dystonia following peripheral trauma

    Article • Deutsche Zeitschrift für Nervenheilkunde, February 2004, Springer Science + Business Media

    Professor Michael Hutchinson

  197. Creutzfeldt-Jakob Disease in Ireland: Epidemiological Aspects 1980–2002

    Article • European Neurology, January 2004, Karger Publishers

    Professor Michael Hutchinson

  198. Progressive multifocal leucoencephalopathy presenting with Parkinsonism

    Article • Deutsche Zeitschrift für Nervenheilkunde, November 2003, Springer Science + Business Media

    Professor Michael Hutchinson

  199. A genome wide scan for association with multiple sclerosis in a N. Irish case control population

    Article • Journal of Neuroimmunology, October 2003, Elsevier

    Professor Michael Hutchinson

  200. Case report: Recurrent temporalis muscle swelling and headache

    Article • Neurology, February 2003, Wolters Kluwer Health

    Professor Michael Hutchinson

  201. Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities

    Article • Neurology, October 2002, Wolters Kluwer Health

    Professor Michael Hutchinson

  202. CADASIL imitating multiple sclerosis: the importance of MRI markers

    Article • Multiple Sclerosis Journal, October 2002, SAGE Publications

    Professor Michael Hutchinson

  203. Leigh disease associated with a novel mitochondrial DNA ND5 mutation

    Article • European Journal of Human Genetics, April 2002, Nature

    Professor Michael Hutchinson

  204. Primary torsion dystonia due to the TOR1A GAG deletion in an Irish family

    Article • Irish Journal of Medical Science (1971 -), January 2002, Springer Science + Business Media

    Professor Michael Hutchinson

  205. The prevalence of "pure" autosomal dominant hereditary spastic paraparesis in the island of Ireland

    Article • Journal of Neurology Neurosurgery & Psychiatry, January 2002, BMJ

    Professor Michael Hutchinson

  206. Interferon- 1b in the treatment of secondary progressive MS: Impact on quality of life

    Article • Neurology, November 2001, Wolters Kluwer Health

    Professor Michael Hutchinson

  207. SPG15, a new locus for autosomal recessive complicated HSP on chromosome 14q

    Article • Neurology, May 2001, Wolters Kluwer Health

    Professor Michael Hutchinson

  208. Hemichorea, moya-moya, and ulcerative colitis

    Article • Movement Disorders, May 2001, Wiley

    Professor Michael Hutchinson

  209. Phenotype of AD-HSP due to mutations in the SPAST gene: Comparison with AD-HSP without mutations

    Article • Neurology, December 2000, Wolters Kluwer Health

    Professor Michael Hutchinson

  210. Ocular microtremor (OMT): a new neurophysiological approach to multiple sclerosis

    Article • Journal of Neurology Neurosurgery & Psychiatry, May 2000, BMJ

    Professor Michael Hutchinson

  211. Age-related cognitive decline in hereditary spastic paraparesis linked to chromosome 2p

    Article • Neurology, April 2000, Wolters Kluwer Health

    Professor Michael Hutchinson

  212. Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia

    Article • Human Molecular Genetics, March 2000, Oxford University Press (OUP)

    Professor Michael Hutchinson

  213. Amnesic syndrome with bilateral mesial temporal lobe involvement in Hashimoto's encephalopathy

    Article • Neurology, February 2000, Wolters Kluwer Health

    Professor Michael Hutchinson

  214. Recurrent optic disc edema with a macular star (ODEMS)

    Article • Eye, September 1999, Springer Science + Business Media

    Professor Michael Hutchinson

  215. A family with pseudodominant Friedreich's ataxia showing marked variation of phenotype between affected siblings

    Article • Journal of Neurology Neurosurgery & Psychiatry, August 1999, BMJ

    Professor Michael Hutchinson

  216. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases

    Article • Journal of Neurology Neurosurgery & Psychiatry, July 1999, BMJ

    Professor Michael Hutchinson

  217. Transient global amnesia: 'amnesia by the seaside' revisited

    Article • Deutsche Zeitschrift für Nervenheilkunde, June 1999, Springer Science + Business Media

    Professor Michael Hutchinson

  218. Mutation of the acetylcholine receptor ɛ‐subunit promoter in congenital myasthenic syndrome

    Article • Annals of Neurology, April 1999, Wiley

    Professor Michael Hutchinson

  219. Rate of Pregnancy-Related Relapse in Multiple Sclerosis

    Article • Survey of Anesthesiology, February 1999, Wolters Kluwer Health

    Professor Michael Hutchinson

  220. Giant cell arteritis presenting as lateral medullary syndrome

    Article • Rheumatology, February 1999, Oxford University Press (OUP)

    Professor Michael Hutchinson

  221. The incidence of sudden unexpected death in epilepsy (sudep) in south dublin and wicklow

    Article • Seizure, October 1998, Elsevier

    Professor Michael Hutchinson

  222. Rate of Pregnancy-Related Relapse in Multiple Sclerosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, July 1998, New England Journal of Medicine (NEJM/MMS)

    Professor Michael Hutchinson

  223. Linkage of AD HSP and cognitive impairment to chromosome 2p: haplotype and phenotype analysis indicates variable expression and low or delayed penetrance

    Article • European Journal of Human Genetics, June 1998, Nature

    Professor Michael Hutchinson

  224. Cognitive impairment in families with pure autosomal dominant hereditary spastic paraparesis

    Article • Brain, May 1998, Oxford University Press (OUP)

    Professor Michael Hutchinson

  225. Autosomal dominant hereditary spastic paraparesis with cognitive loss linked to chromosome 2p

    Article • Brain, April 1998, Oxford University Press (OUP)

    Professor Michael Hutchinson

  226. Two families with autosomal recessive spastic paraplegia, pigmented maculopathy, and dementia

    Article • Journal of Neurology Neurosurgery & Psychiatry, November 1997, BMJ

    Professor Michael Hutchinson

  227. Cranial and peripheral neuropathy due to Epstein-Barr virus infection.

    Article • Postgraduate Medical Journal, July 1997, BMJ

    Professor Michael Hutchinson

  228. A Family with Hereditary Spastic Paraparesis and Epilepsy

    Article • Epilepsia, April 1997, Wiley

    Professor Michael Hutchinson

  229. Superficial siderosis of the central nervous system

    Article • Irish Journal of Medical Science (1971 -), July 1996, Springer Science + Business Media

    Professor Michael Hutchinson

  230. Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL)

    Article • Annals of Neurology, November 1995, Wiley

    Professor Michael Hutchinson

  231. Do Alpha-Blockers Have a Role in Lower Urinary Tract Dysfunction in Multiple Sclerosis?

    Article • The Journal of Urology, April 1995, Elsevier

    Professor Michael Hutchinson

  232. Do Alpha-Blockers Have a Role in Lower Urinary Tract Dysfunction in Multiple Sclerosis?

    Article • The Journal of Urology, April 1995, Elsevier

    Professor Michael Hutchinson

  233. Neuroleptic malignant syndrome.

    Article • Journal of Neurology Neurosurgery & Psychiatry, March 1995, BMJ

    Professor Michael Hutchinson

  234. The functional limitations profile may be a valid, reliable and sensitive measure of disability in multiple sclerosis

    Article • Deutsche Zeitschrift für Nervenheilkunde, January 1995, Springer Science + Business Media

    Professor Michael Hutchinson

  235. The influence of pregnancy on multiple sclerosis: a European multicentric prospective study — First results

    Article • Journal of Neuroimmunology, January 1995, Elsevier

    Professor Michael Hutchinson

  236. Amnesic syndrome after theophylline associated seizures: iatrogenic brain injury.

    Article • Journal of Neurology Neurosurgery & Psychiatry, May 1994, BMJ

    Professor Michael Hutchinson

  237. Worsening of myasthenia gravis on treatment with imipenem/cilastatin.

    Article • Journal of Neurology Neurosurgery & Psychiatry, March 1994, BMJ

    Professor Michael Hutchinson

  238. Bipolar affective disorder prior to the onset of multiple sclerosis

    Article • Acta Neurologica Scandinavica, December 1993, Wiley

    Professor Michael Hutchinson

  239. Pregnancy in multiple sclerosis.

    Article • Journal of Neurology Neurosurgery & Psychiatry, October 1993, BMJ

    Professor Michael Hutchinson

  240. Psychosis and multiple sclerosis

    Article • The British Journal of Psychiatry, March 1993, Royal College of Psychiatrists

    Professor Michael Hutchinson

  241. An epidemiological study of Wilson's disease in the Republic of Ireland.

    Article • Journal of Neurology Neurosurgery & Psychiatry, March 1993, BMJ

    Professor Michael Hutchinson

  242. Plantar power: reproducibility of the plantar response.

    Article • BMJ, February 1992, BMJ

    Professor Michael Hutchinson

  243. Suxamethonium is contraindicated in the Guillain-Barre syndrome.

    Article • Journal of Neurology Neurosurgery & Psychiatry, November 1991, BMJ

    Professor Michael Hutchinson

  244. Livedo reticularis and dementia

    Article • Deutsche Zeitschrift für Nervenheilkunde, August 1990, Springer Science + Business Media

    Professor Michael Hutchinson

  245. Irish Neurological association

    Article • Irish Journal of Medical Science (1971 -), June 1990, Springer Science + Business Media

    Professor Michael Hutchinson, Paul McCullagh

  246. Progressive multifocal leukoencephalopathy-remission with cytarabine

    Article • Journal of Infection, January 1990, Elsevier

    Professor Michael Hutchinson

  247. Benign recurrent multiple mononeuropathy in Wegener's granulomatosis.

    Article • Journal of Neurology Neurosurgery & Psychiatry, July 1989, BMJ

    Professor Michael Hutchinson

  248. Contrast sensitivity in multiple sclerosis measured by Cambridge Low Contrast Gratings: a useful clinical test?

    Article • Journal of Neurology Neurosurgery & Psychiatry, June 1989, BMJ

    Professor Michael Hutchinson

  249. Chronic hypothermia in multiple sclerosis.

    Article • Journal of Neurology Neurosurgery & Psychiatry, June 1987, BMJ

    Professor Michael Hutchinson

  250. Three possible laboratory indexes of disease activity in multiple sclerosis

    Article • Neurology, March 1987, Wolters Kluwer Health

    Professor Michael Hutchinson

  251. Peripheral blood T lymphocyte changes in multiple sclerosis: a marker of disease progression rather than of relapse?

    Article • Journal of Neurology Neurosurgery & Psychiatry, August 1986, BMJ

    Professor Michael Hutchinson

  252. Late responses as aids to diagnosis in peripheral neuropathy.

    Article • Journal of Neurology Neurosurgery & Psychiatry, August 1986, BMJ

    Professor Michael Hutchinson

  253. Royal academy of medicine in Ireland section of medicine

    Article • Irish Journal of Medical Science (1971 -), December 1985, Springer Science + Business Media

    Professor Michael Hutchinson

  254. Oligoclonal bands in multiple sclerosis: An index of disease activity?

    Article • Neurology, October 1985, Wolters Kluwer Health

    Professor Michael Hutchinson

  255. Suspected and clinically definite multiple sclerosis: the relationship between CSF immunoglobulins and clinical course.

    Article • Journal of Neurology Neurosurgery & Psychiatry, October 1985, BMJ

    Professor Michael Hutchinson

  256. Suppressor T cell changes in active multiple sclerosis: analysis with three different monoclonal antibodies.

    Article • Journal of Neurology Neurosurgery & Psychiatry, October 1985, BMJ

    Professor Michael Hutchinson

  257. Irish neurological association

    Article • Irish Journal of Medical Science (1971 -), April 1984, Springer Science + Business Media

    Professor Michael Hutchinson

  258. Visual evoked responses and immunoglobulin abnormalities in the diagnosis of multiple sclerosis

    Article • Acta Neurologica Scandinavica, August 1983, Wiley

    Professor Michael Hutchinson

  259. Neurological lupus erythematosus with tonic seizures simulating multiple sclerosis.

    Article • Journal of Neurology Neurosurgery & Psychiatry, June 1983, BMJ

    Professor Michael Hutchinson

  260. Papilledema in two patients with acromegaly and intrasellar pituitary tumors

    Article • Archives of Internal Medicine, October 1981, American Medical Association (AMA)

    Professor Michael Hutchinson

  261. GENERAL DISEASE IN 120 NECROPSY-PROVEN CASES OF MULTIPLE SCLEROSIS

    Article • Neuropathology and Applied Neurobiology, July 1978, Wiley

    Professor Michael Hutchinson

  262. Acute optic neuritis and the prognosis for multiple sclerosis.

    Article • Journal of Neurology Neurosurgery & Psychiatry, March 1976, BMJ

    Professor Michael Hutchinson

  263. Measles-virus-specific IgG in optic neuritis and in multiple sclerosis after optic neuritis.

    Article • BMJ, January 1976, BMJ

    Professor Michael Hutchinson